caa a22 4500 465777430 CHVBK 20180323111946.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00918481 doi (NATIONALLICENCE)springer-10.1007/BF00918481 Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy [Elektronische Daten] [R. Gurny, J. Ryser, C. Tabatabay, M. Martenet, P. Edman, O. Camber] The aim of the present study was to quantify in man the distribution and clearance of two aqueous sodium hyaluronate (SH) solutions of 0.125% and 0.250% after the administration of 25 μl onto the cornea. Isotonic phosphate buffer (PB) was used as a reference instillation. No systemic or local medication was given to the seven 18- to 30-year-old, healthy male volunteers. A detailed evaluation of the anterior segment of the eye, as well as a Schirmer test and a break-up time measurement, yielded results within the normal range. The clearance of 0.125% and 0.250% SH solutions radiolabelled with sodium pertechnetate Tc-99m was measured by gamma scintigraphy and compared with that of a PB solution tagged with the same radiolabel. There was no statistically significant difference between the quantities of 0.125% SH and PB solutions remaining in the precorneal space at 20 min (paired t-test,P=0.78,n=7). However, in comparing the 0.250% SH with the PB solution, we observed a statistically significant difference (P=0.01,n=7) in the amount remaining in the precorneal space after the same interval. Actually, 53% of the radiolabelled 0.250% SH solution remained on the cornea as compared with 30% for the 0.125% SH solution and 18.3% for the PB solution. These results suggest that an SH solution of 0.250% might have a prolonged residence time on the precorneal surface, and that SH could therefore be used as an additive in various drug-release systems for the eye. Springer-Verlag, 1990 Gurny R. Department of Pharmaceutical Technology, University of Geneva, 30 quai Ernest-Ansemet, CH-1211, Geneva 4, Switzerland aut Ryser J. Department of Nuclear Medicine, University Hospital of Geneva, Switzerland aut Tabatabay C. Department of Ophthalmology, University Hospital of Geneva, Switzerland aut Martenet M. Department of Pharmaceutical Technology, University of Geneva, 30 quai Ernest-Ansemet, CH-1211, Geneva 4, Switzerland aut Edman P. Department of Pharmaceutical R & D, Pharmacia-Leo Therapeutics AB, Uppsala, Sweden aut Camber O. Department of Pharmaceutical R & D, Pharmacia-Leo Therapeutics AB, Uppsala, Sweden aut Graefe's Archive for Clinical and Experimental Ophthalmology Springer-Verlag 228/6(1990-11-01), 510-512 0721-832X 228:6<510 1990 228 417 https://doi.org/10.1007/BF00918481 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00918481 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gurny R. Department of Pharmaceutical Technology, University of Geneva, 30 quai Ernest-Ansemet, CH-1211, Geneva 4, Switzerland aut NATIONALLICENCE 700 1- Ryser J. Department of Nuclear Medicine, University Hospital of Geneva, Switzerland aut NATIONALLICENCE 700 1- Tabatabay C. Department of Ophthalmology, University Hospital of Geneva, Switzerland aut NATIONALLICENCE 700 1- Martenet M. Department of Pharmaceutical Technology, University of Geneva, 30 quai Ernest-Ansemet, CH-1211, Geneva 4, Switzerland aut NATIONALLICENCE 700 1- Edman P. Department of Pharmaceutical R & D, Pharmacia-Leo Therapeutics AB, Uppsala, Sweden aut NATIONALLICENCE 700 1- Camber O. Department of Pharmaceutical R & D, Pharmacia-Leo Therapeutics AB, Uppsala, Sweden aut NATIONALLICENCE 773 0- Graefe's Archive for Clinical and Experimental Ophthalmology Springer-Verlag 228/6(1990-11-01), 510-512 0721-832X 228:6<510 1990 228 417 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer